T. Rowe Price Associates
THRX

T. Rowe Price Associates’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

T. Rowe Price Associates’s Portfolio THRX Stock Details THRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,216,500
Closed -$3.27M – 2938
2023
Q3 		$3.27M Sell
1,216,500
-39,509
-3% -$155K ﹤0.01% 1300
2023
Q2 		$11.7M Sell
1,256,009
-69,556
-5% -$685K ﹤0.01% 1051
2023
Q1 		$11.8M Buy
1,325,565
+11,657
+0.9% +$114K ﹤0.01% 1028
2022
Q4 		$6.54M Sell
1,313,908
-67,581
-5% -$396K ﹤0.01% 1129
2022
Q3 		$8.01M Sell
1,381,489
-3,794
-0.3% -$26.8K ﹤0.01% 1103
2022
Q2 		$7.66M Sell
1,385,283
-51,333
-4% -$424K ﹤0.01% 1360
2022
Q1 		$16.3M Buy
1,436,616
+137,129
+11% +$1.47M ﹤0.01% 1285
2021
Q4 		$16.2M Buy
+1,299,487
New +$19.6M ﹤0.01% 1331

Other funds holding THRX

O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $155M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
HCM
Highbridge Capital Management New York $1.58B AUM 31.19% 1-Year Est. Return